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Summary  13 
Microcephaly is an important sign of neurological malformation and predictor of future disability. 14 
The recent outbreak of Zika virus and congenital Zika infection has brought the world’s attention 15 
to the links between infection and microcephaly. However, Zika virus is only one of the 16 
infectious causes of microcephaly and, though the contexts in which they occur vary greatly, all 17 
are of concern. In this review, we summarise important aspects of the major congenital infections 18 
that can cause microcephaly, describing the epidemiology, transmission, clinical features, 19 
pathogenesis and long-term consequences. We include the infections that cause substantial 20 
impairment: cytomegalovirus, herpes simplex virus, rubella virus, Toxoplasma gondii, and Zika 21 
virus. We highlight potential issues with the classification of microcephaly and show how some 22 
infants affected by congenital infection may be missed or incorrectly diagnosed. While the 23 
world’s current focus on Zika virus is remarkable, preventing all infectious causes of 24 
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microcephaly and appropriately managing its consequences remain important global public health 25 
priorities.  26 
 27 
Introduction  28 
This review was conducted in response to the recent outbreak of microcephaly associated with congenital 29 
Zika virus (ZIKV) infection, first identified in Latin America. Attention has been drawn to ZIKV because 30 
the previously unknown congenital syndrome was discovered in a susceptible population and can 31 
potentially affect a very large number of infants. ZIKV however is one of a group of infectious diseases 32 
that can be transmitted to the fetus and cause microcephaly and the microcephaly is likely to represent the 33 
tip of the iceberg in terms of developmental abnormalities, forming part of a syndrome for each infection. 34 
Understanding the different causes of microcephaly will help clinicians, researchers, and hopefully policy 35 
makers contextualize the recent outbreak and can be applied to help the individual child, as well as to 36 
inform appropriate planning of services for the population.  37 
In this article, we review the major congenital infections that can cause microcephaly, focusing 38 
on those with the largest disease burden and the strongest evidence for causation: 39 
cytomegalovirus (CMV), herpes simplex virus (HSV), rubella virus, Toxoplasma gondii (T. 40 
gondii), and ZIKV. We describe the epidemiology, pathogenesis, transmission, clinical features 41 
and long-term disability in childhood. Less frequent causes of primary microcephaly are not 42 
considered here. While congenital syphilis has a high disease burden in regions affected by ZIKV 43 
and varicella virus has recognised neurotropic properties, published reports describing primary 44 
microcephaly in the context of these two infections are scarce. 45 
 46 
Microcephaly 47 
Microcephaly is a clinical diagnosis made at or after birth that describes a small head. It does not 48 
necessarily mean abnormal brain development and some children with microcephaly are healthy. 49 
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An accepted definition of microcephaly is occipito-frontal head circumference (OFC)>2 standard 50 
deviations below the median (<-2 z-scores), for gestational age and sex in an appropriate healthy 51 
reference population, with severe microcephaly defined as <-3 z-scores.1-3 The reference range 52 
and population from which a definition is taken can vary, for example country-specific ranges, 53 
the World Health Organization (WHO) child-growth ranges for term infants, the Fenton ranges 54 
for preterm infants, and the InterGrowth reference ranges are all used.4 This limits the 55 
comparability of microcephaly prevalence estimates and accounts for a proportion of the global 56 
variability in rates. The WHO currently recommends the Intergrowth-21 criteria if the gestational 57 
age is known and the WHO Child Growth Standards if it is not.1,5,6 In addition, and probably 58 
more importantly, inconsistency in frequency and rigour of measurement, and completeness of 59 
reporting, makes population prevalences difficult to ascertain. A recent study across Europe 60 
found a prevalence, excluding genetic conditions, of 1·53 (95% CI 1·16, 1·96) per 10,000 61 
“births” (including live births, fetal deaths from 20 weeks gestation and termination of pregnancy 62 
for fetal anomaly). Including genetic conditions would increase the prevalence to approximately 63 
2·0 per 10,000. There was considerable variation in the estimates from 0·41/10,000 in Portugal to 64 
4·25/10,000 in UK and in the definition of microcephaly (<-2 z-scores, <-3 z-scores and clinical 65 
decisions), the reference ranges used and methods of ascertainment.7  66 
Microcephaly can be divided into primary- i.e. develops before 32 weeks’ gestation8 or birth9- 67 
and secondary- i.e. microcephaly that develops after this time. Primary microcephaly, the focus of 68 
this review, is generally due to disturbed neurogenesis (mitosis or progenitor cell function) or 69 
death of neuronal progenitors.9,10 Secondary microcephaly normally relates to the postnatal 70 
development and maturation of neurons (dendritic processes and synaptic connections).8 Infection 71 
can lead to both primary or secondary microcephaly but this differentiation is often not possible if 72 
the appropriate head circumference measurements are not taken. In high-income countries, 73 
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microcephaly is predominantly due to non-infectious causes,11,12 including genetic abnormalities, 74 
nutritional deficiencies, hypothyroidism, brain injury, alcohol, drugs, and placental 75 
insufficiency.8,9 A multi-centre retrospective analysis from Germany found that only 25 of 403 76 
(6·2%) cases of microcephaly (for which a cause was identified) were due to maternal infections 77 
in pregnancy.12 The prevalence of in utero or perinatal infections in cases of severe microcephaly 78 
is higher e.g. 46 of 284 (16%) cases in New York 2013-15.13 79 
A reduction in head size may be associated with intrauterine growth restriction, for example with 80 
CMV and ZIKV. This can be either symmetrically or asymmetrically reduced in size in relation 81 
to the overall anthropometry of the infant. The gestation at which an insult occurs, will determine 82 
when microcephaly is clinically detectable. An infection close to birth may result in brain damage 83 
but with a normal head circumference. Recent data suggest that microcephaly may be poorly 84 
sensitive for screening infants severely affected by congenital ZIKV infection, particularly as this 85 
consists of many other manifestations.14 Clinically apparent, microcephaly is one of many fetal 86 
brain abnormalities that can lead to later neurodevelopmental sequelae.15 Although a clinical 87 
diagnosis of microcephaly with normal brain imaging does not necessarily mean impaired brain 88 
growth, a reduction in skull volume is indicative of underlying cerebral cortical volume loss.8,16 A 89 
study of Finnish infants admitted to a neonatal ward for example, showed that a one standard 90 
deviation increase in head circumference at birth was associated with a 0·8-1·5 unit increase in 91 
cognitive scores at 56 months.17  92 
If we use microcephaly to screen for congenital diseases, and if OFC is normally distributed in 93 
the reference population, 2·3% of the population will be classified as having microcephaly, many 94 
of whom will be healthy. Conversely, many neonates with congenital infections that affect the 95 
brain will not have severe enough manifestations to cause microcephaly. To illustrate this, we 96 
simulate two scenarios (Figure 1). A definition of <-3 z-scores (0·1% of the population)18,19 is 97 
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expected to be 99·9% specific, although much less sensitive (57%).4 An assessment of 1501 cases 98 
of suspected microcephaly reported to the Brazilian notification system, showed that 21·7% of 99 
notified cases classified as ‘definite or probable’ had a normal head circumference (>-2 z-scores) 100 
and this cut-off had a sensitivity of 83% and specificity of 98%.14 So although microcephaly is a 101 
good screening diagnosis for brain damage caused by a congenital infection, some cases will be 102 
normal and cases with neurological damage may not be identified. Further tools must therefore be 103 
employed.  104 
 105 
Pathogenesis and embryology 106 
The central nervous system becomes established from day 22 of embryonic development when 107 
the neural tube is formed.20 The embryonic brain is initially composed entirely of proliferative 108 
neuronal progenitors which reside within the ventricular zone (VZ) bordering the neural tube 109 
lumen. However, with subsequent development, neurons begin to emerge and a new population 110 
of deeper subventricular zone (SVZ) neural progenitors arises. Proliferation of the SVZ cells 111 
contributes to further expansion of the brain’s neuronal population. Proliferative VZ and SVZ 112 
neuronal progenitors persist until around mid-gestation, providing a target for pathogens via the 113 
cerebral blood supply which is now fully established. Experimental evidence shows that 114 
regulation of neural progenitor numbers and sub-types is vital for controlling brain size and 115 
morphology (Figure 2). For example, mouse studies reveal that abnormal expansion of the VZ or 116 
SVZ neural progenitors increases brain size and produces macrocephaly.21,22 In contrast, a 117 
reduction in neural progenitor numbers due to cell death, cell cycle arrest or premature neuronal 118 
differentiation reduces brain size and produces microcephaly.23-26 119 
 120 
The pathogenesis of CMV, HSV, rubella and ZIKV is described below. Little information is 121 
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available on the mechanisms of congenital brain infection for T. gondii, where additional research 122 
is needed. The congenital infections we describe in this paper (summarised in Table 1) are 123 
responsible for a range of developmental brain defects, with the more severe cases occurring after 124 
infection during the first trimester of gestation, when the neural progenitors are actively 125 
multiplying and producing neurons (Figure 2).27-36Analysis of material from aborted human 126 
fetuses confirms that brain cells are susceptible to viral infection (ZIKV,30 CMV,37 HSV35,38 and 127 
rubella39). Moreover, human cell culture systems demonstrate that neural progenitors are targeted 128 
by these pathogens (ZIKV brain organoids40,41; HSV iPS-derived cell culture42; ZIKV 129 
neurospheres 43; CMV neural precursors37). This research suggests that perturbation of neural 130 
progenitor populations may be the main cause of infection-related microcephaly.  131 
 132 
CMV 133 
CMV is capable of altering progenitor and neuronal fates through the downregulation of 134 
multipotency markers including Sox2 and Nestin.44,45 Neuronal differentiation has been found to 135 
be inhibited or delayed by CMV37,46,47 or to occur prematurely after infection.44 Recently, a new 136 
molecular mechanism downstream of CMV brain infection has emerged: PPARγ (peroxisome 137 
proliferator-activated receptor gamma) was found to increase following CMV infection of human 138 
neural stem cells and human fetal brain sections. Activation of PPARγ function alone was 139 
sufficient to impair neuronal differentiation, and a PPARγ inhibitor restored normal 140 
differentiation. Moreover, nuclear PPARγ was detected in the brains of congenitally infected 141 
fetuses.47 These findings support a role for PPARγ in mediating congenital CMV brain disease. 142 
 143 
HSV 144 
HSV can infect multiple brain cell types (human35,38, in vitro 42 and mouse48) but how this leads 145 
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to microcephaly is unclear. Infected organs including the brain, show tissue necrosis post-146 
mortem.36 In vitro and animal studies suggest that HSV may initially induce an immune response 147 
that stimulates neural stem cell proliferation. Subsequently, brain infiltration by CD8(+) T cells 148 
limits proliferation through the stimulation of interferon-gamma.49 Operation of a similar 149 
immune-mediated mechanism following congenital brain infection leading to microcephaly is 150 
possible but remains to be verified. 151 
 152 
Rubella 153 
The mechanisms by which rubella virus induces microcephaly remain largely unknown. Most 154 
human embryonic tissues can be infected by rubella virus39,50 and brain vessels have been found 155 
to degenerate following rubella infection.50-52 This suggests that a neurodegenerative mechanism 156 
could be a potential underlying cause of rubella-induced microcephaly in humans. There is also 157 
indirect evidence that rubella infection can slow the rate of cell division although this has not 158 
been confirmed in human neural cells in culture.28  159 
 160 
ZIKV 161 
Congenital viral infections and brain development studies have benefited from recent advances in 162 
the growth of human cells in 3-dimensional (3D) culture. Cell aggregates called ‘neurospheres’ 163 
are formed initially but with continued culture they can form ‘organoids’ that mimic some 164 
features of true organs. Studies employing these techniques have confirmed that neural 165 
progenitors (ventricular zone (VZ) and later subventricular zone (SVZ)) are indeed the 166 
commonest brain cell type infected by ZIKV (brain organoids40,41 and neurospheres43). The 167 
exposure of these 3D cell cultures to the virus mimics many features of microcephaly in humans, 168 
including a decrease in neuronal production, reduced VZ thickness and overall smaller 169 
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organoids.40,41,53 This reduction in growth seems to result from cell cycle arrest54 and/or an 170 
increase in cell death,41,43,53,54 and could indeed explain the microcephaly phenotype observed in 171 
ZIKV-infected human fetuses. Entry of ZIKV into neural progenitors has been suggested to occur 172 
via viral receptor AXL, which mediates ZIKV and dengue virus entry into human skin cells,55 173 
and  is strongly expressed in VZ and SVZ neural progenitors.56,57 However, a recent study using 174 
human brain organoids revealed that genetic ablation of AXL alone is unable to prevent ZIKV 175 
infection, suggesting that other cell adhesion or entry factors may be involved.58 Human fetal 176 
organotypic slice culture studies reveal that phospho-TANK Binding Kinase 1 (pTKB1), 177 
relocates from centrosomes to mitochondria following ZIKV infection producing mitotic defects 178 
and supernumerary centrosomes that may exacerbate cell death.57,59 Injection of ZIKV into 179 
pregnant macaques and mice, or into the mouse brain, has recently confirmed some of the 180 
observations from human in vitro culture systems.60-62 Dang and colleagues also discovered that 181 
ZIKV infection activates TLR3 (involved in activation of an immune response) and that TLR3 182 
inhibition can attenuate apoptosis and decrease growth induced by viral infection.40 The 183 
comparison of transcriptome profiles derived from infected and non-infected animal tissue also 184 
highlights new potential molecular viral targets. These include the down-regulated expression of 185 
an extensive list of genes (all centrosome-related) previously associated with autosomal recessive 186 
primary microcephaly (ASPM, CENPF, MCPH1, STIL, Cep135).60,61 This suggests that the 187 
underlying pathogenesis of autosomal recessive and virally induced microcephalies may be 188 
similar, although this is yet to be confirmed. 189 
 190 
Infection in pregnancy: Epidemiology, transmission and clinical features  191 
Table 1 describes the epidemiology and clinical features of the main infections associated with 192 
microcephaly in pregnant women/adults.  193 
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 194 
CMV 195 
Most women of childbearing age in low- and middle-income country (LMICs) have long-lasting 196 
immunity from prior CMV infection but viral reactivation can take place in pregnancy or during 197 
periods of immunosuppression. In Sub-Saharan Africa, Latin America and South Asia, over 90% 198 
of the general population have IgG antibodies compared to a seroprevalence of 40-60% in high-199 
income countries.63-68 Prevalence of congenital CMV infection in high-income countries is 200 
estimated to be  0·7% of all live births, or 1-5% in low-income countries.63,66,69 201 
The risk of in utero transmission varies according to whether maternal CMV infection is primary, 202 
a reactivation of latent infection, or superinfection with another CMV strain.63 Primary infection 203 
has the highest risk of in-utero transmission and fetal disease is more severe, particularly when it 204 
occurs earlier in pregnancy. Overall, most cases of congenital CMV infection result from non-205 
primary maternal infection but most of these are asymptomatic.70 The risk of transmission 206 
increases with advancing gestational age, with 35% of mothers who have a primary infection in 207 
the first trimester giving birth to infected newborns, compared to 65% who are infected in the 208 
third trimester.71 Rates of transmission in non-primary infection are less certain but are generally 209 
reported to be lower.63,72,73 The risk of congenital CMV infection is increased by maternal HIV 210 
infection both for HIV exposed uninfected and HIV infected infants.63 In-utero HIV transmission 211 
has been shown to be particularly associated with congenital CMV.74 212 
  213 
 214 
HSV 215 
Primary microcephaly is a relatively rare complication of perinatal HSV infection and is mainly 216 
found in association with in-utero infection which accounts for only 5% of cases.75 Global 217 
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average seroprevalence is 18% amongst women of childbearing age but this includes huge 218 
variations: from 4·1% in Japan to 62% in East Asia and 70% in Sub-Saharan Africa.76,77 Neonatal 219 
infection at the time of birth from mothers with symptomatic genital infection is more common 220 
but does not cause primary microcephaly.  221 
 222 
Rubella 223 
Rubella is a vaccine-preventable disease and rates of infection are largely dependent on the 224 
coverage of immunisation programmes. The global incidence of congenital rubella syndrome has 225 
reduced from 0·1-0·2 per 1000 live births prior to vaccination to near elimination (<0·01 per 226 
100,000 live births) in areas with comprehensive vaccination rates.78 Vaccination programmes 227 
were widespread in most countries in 2014 except in Sub-Saharan Africa and South Asia.79 228 
Despite widespread vaccination programmes an estimated 9.4% of pregnant women remain 229 
seronegative worldwide and therefore susceptible to infection.80 In areas without vaccination 230 
programmes, incidence of congenital rubella syndrome has been estimated at 19-283 per 100,000 231 
live births in the African region and 18-309 per 100,000 live births in the South Asian region.78  232 
 233 
T. gondii  234 
Most women of childbearing age in Latin America (51-72%), Central Europe (58%), and West 235 
Africa (54-77%) have specific IgG antibodies to T. gondii.81 Conversely, relatively few women of 236 
childbearing age are found to be seropositive in South-east Asia, China and Korea (4-39%), 237 
Scandinavia (11-28%), and the United States (15%).81,82 Mother-to-child transmission 238 
predominantly occurs following primary infection during pregnancy. The global incidence of 239 
congenital toxoplasmosis is estimated at 1·5 cases per 1000 live births (95% credible interval 1·4, 240 
1·6), being highest in some Latin America countries (average, 3·4 per 1000) and lowest in parts 241 
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of Europe (0·5 per 1000).83 The risk of congenital infection may rise due to reactivation of T. 242 
gondii from immunosuppression, for example resulting from HIV.84  243 
 244 
ZIKV 245 
ZIKV has been described for over 60 years with intermittent case reports until outbreaks in Yap 246 
Island (estimated 73% (95% CI 68, 77) of population infected) in 2007, French Polynesia (up to 247 
66% IgG +ve) in 2013 and Brazil in 2015.55,85,86 It is currently documented in 84 countries or 248 
subregional areas and 31 have reported microcephaly or neurological malformations associated 249 
with ZIKV.87 The prevalence of suspected disease in women of childbearing age is 5400 per 250 
100,000 in Brazil.88  251 
 252 
Laboratory diagnosis during pregnancy  253 
Any pregnant woman presenting with fever and/or rash should be evaluated for risk of infections 254 
that are potentially transmitted to the fetus. There are many infectious causes of rash, for example 255 
Parvovirus B19, measles and varicella zoster, and extensive guidelines exist describing when 256 
testing should be done.89  257 
During the acute infection, laboratory confirmation is usually only possible where clinical 258 
symptoms are present in the mother. Primary CMV, HSV, T. gondii, and ZIKV infections may be 259 
asymptomatic and therefore the opportunity to confirm acute infection can be missed.90 In acute 260 
symptomatic maternal infection, ZIKV and rubella can be detected in serum, blood, oral fluid or 261 
urine by PCR amplification of nucleic acid and may precede the development of IgM antibodies. 262 
Acute primary maternal HSV can be diagnosed by viral PCR and the presence of IgM antibodies 263 
but usually only when oral or genital lesions are present. Virus may be detected for up 10 weeks 264 
in serum following acute ZIKV29 and two weeks following acute rubella91 while CMV and HSV 265 
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are frequently shed asymptomatically from mucosal epithelia.92,93 Detection of T. gondii IgA is 266 
the most sensitive indicator of congenital infection in the child.94 CMV shedding in oral fluid 267 
may occur both during primary infection and asymptomatic reactivation and is therefore not 268 
always a reliable indicator of acute primary infection. Detection of virus needs to be interpreted 269 
in the light of serological results.66  270 
 271 
Serological testing in pregnant women 272 
For rubella, T. gondii and CMV commercial enzyme immunoassays are routinely available for 273 
antibody detection. For rubella and toxoplasmosis cases, serological diagnosis of acute primary 274 
infection relies on detection of acute phase IgM antibodies, which for most do not reach adequate 275 
levels until one week following acute infection. For all three, paired IgG samples taken at least 276 
10-14 days apart should also be obtained to confirm seroconversion. A fourfold rise in antibody 277 
titre is indicative of recent although not necessarily primary infection.94 T. gondii IgM antibodies 278 
are commonly detected by ELISA in acute infections, but may persist for several months.95 High 279 
levels of IgG antibodies may also be present during the acute phase of infection.96  280 
In general, detection of CMV IgM, has been shown to lack sensitivity and specificity, especially 281 
in conditions of immune dysfunction. A positive CMV IgM is associated with primary infection 282 
in only 10% of cases. To distinguish between acute and chronic infections, ELISA-based IgG 283 
avidity tests are widely recommended: low-avidity antibodies are typically found over the first 284 
weeks, while high-avidity IgG predominates in the chronic phase.93  285 
IgM and IgG antibody tests for dengue, West Nile fever and ZIKV members of the flaviviridae 286 
family share considerable epitope cross-reactivity. Plaque reduction neutralising tests can be used 287 
to differentiate closely related viruses but is too complex for routine diagnosis especially in non-288 
specialised laboratories.  289 
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 290 
In-utero testing 291 
In the event that acute maternal infection with any of the above pathogens is considered to pose a 292 
risk, infection of the infant can be investigated where possible by amplification of pathogen 293 
nucleic acid from amniotic fluid. Amniotic fluid samples are typically obtained at 18 weeks 294 
gestation to determine fetal infection with T. gondii and guide therapy.97 In CMV infection, there 295 
is a 6-8 week window between maternal infection and being able to detect the virus in amniotic 296 
fluid. PCR has high sensitivity when performed at the correct time (20-21 weeks gestation or 7 297 
weeks after maternal infection) and, when combined with culture, nearly all congenital infection 298 
can be diagnosed.63 PCR testing of amniotic fluid for HSV is possible but does not seem to 299 
correlate with neonatal infection,98 and has recently been shown to be possible with ZIKV.99 300 
 301 
Screening  302 
Childhood immunisation programmes against rubella are routinely available in 147 countries, 303 
with an estimated global coverage of 46%.100 Pregnant women may be screened for rubella 304 
antibody and those in whom levels are absent or low, offered post-partum vaccination. Recently, 305 
high coverage levels of immunisation have led to some high-income countries to drop rubella 306 
screening. Prenatal screening for toxoplasmosis is routinely undertaken in Austria, France and 307 
Slovenia and neonatal screening in Denmark, Ireland and some parts of USA and Brazil.95 In 308 
France, women who develop high titres of IgM antibodies or evidence of seroconversion 309 
indicative of primary infection during pregnancy are offered fetal screening and treatment with 310 
spiramycin or pyrimethamine-sulphonamide. Severe sequelae from congenital toxoplasmosis are 311 
now rarely seen after the current approach of systematic prenatal screening and treatment was 312 
implemented in France.101 Screening for CMV in some high-income countries and for ZIKV in 313 
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countries with high levels of transmission are being considered however, it is not currently 314 
recommended for either. 315 
 316 
Clinical presentation at birth 317 
Whilst infection can cause both primary and secondary microcephaly, the main focus of this 318 
review is the effect of congenital infections on neurogenesis or antenatal neural progenitor death 319 
usually associated with primary microcephaly, i.e. it is present at birth. Evaluation of an infant 320 
with suspected microcephaly at birth seeks to meet three goals: (1) confirm the diagnosis of 321 
microcephaly; (2) identify the cause and attempt syndromic diagnosis; and (3) aid prognosis and 322 
guide initial treatment where appropriate.  323 
Measurement of the OFC (illustrated in Figure 3) is used as a screening examination to identify 324 
neonates who are likely to have an underlying neurological condition. A full antenatal history 325 
with particular focus on acquired environmental insults, maternal serology, antenatal fetal growth 326 
measurements where available, and family history of microcephaly and neurological conditions 327 
are essential to identify possible causes. Systemic examination, including ophthalmology and 328 
audiology, will help in identifying associated abnormalities in other organ systems. Cranial 329 
ultrasound (crUS) can be used to screen for anatomical abnormalities where available. Features 330 
suggestive of congenital infections in an infant with microcephaly are: maternal history of 331 
infection during pregnancy, indicative antenatal maternal serology results, clinical features in the 332 
neonate (Panel) and calcifications on brain imaging. In patients with these features, a more 333 
specific work-up is required, including serological testing to confirm specific infectious causes, 334 
other laboratory investigations, and further neuroimaging.  335 
  336 
Identifying Specific Infectious Causes 337 
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Common clinical features for each infection are shown in the appendix and a summary of 338 
diagnosis and treatment recommendations are given in Table 2. Much of this information is based 339 
on historical cohorts and case studies and is therefore potentially prone to bias. Individual patients 340 
may present with different signs and symptoms.  341 
 342 
CMV 343 
Most neonates with congenital CMV are asymptomatic but common manifestations in 344 
symptomatic neonates include intra-uterine growth restriction, sensorineural hearing loss, 345 
petechiae, and jaundice. Neurological sequelae are observed in 60-90% of those with clinical 346 
symptoms at birth,102 although biases from early cohort studies may overestimate this.72,103,104 Up 347 
to 15% of infants that are asymptomatic at birth may go on to develop symptoms later in 348 
childhood.63,102,104  349 
 350 
HSV 351 
Infection can occur in utero, intrapartum or postnatally. In utero infection is classically associated 352 
with a triad of cutaneous, ophthalmological and neurological abnormalities (including 353 
microcephaly). Vesicular lesions may or may not be present and often develop late. Perinatal 354 
infection presents in 3 main ways: disseminated disease affecting multiple sites, CNS disease or 355 
skin/eyes/mouth limited infection.75,105  356 
 357 
Rubella 358 
Fetal abnormalities resulting from in utero transmission of rubella range in severity according to 359 
the gestation at the time of infection. Infection in the first trimester is associated with more severe 360 
abnormalities.106 Symptomatic infection in the infant is referred to as congenital rubella syndrome 361 
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(CRS) with a classic triad of cataracts, sensorineural deafness and cardiac defect (e.g. patent 362 
ductus arteriosus, ventricular septal defect).107 Estimates of the frequency of microcephaly in 363 
CRS vary but have been reported to be as high as a third of cases overall.108  364 
 365 
T. gondii  366 
Approximately 24% of live born infants infected with T. gondii are symptomatic at birth.109 The 367 
classic signs originally described by Sabin (chorioretinitis, microcephaly or hydrocephalus, and 368 
widespread intracranial calcifications) are relatively infrequent, but highly suggestive of the 369 
diagnosis of congenital toxoplasmosis. More severe manifestations occur in infections earlier in 370 
gestation. Intracranial lesions, for example, are seen in up to 40% of congenital infections 371 
acquired before 5 weeks of pregnancy but in less than 10% of those acquired beyond 20 weeks.109 372 
12·5% of liveborn infants with congenital toxoplasmosis develop severe neurological sequelae;110 373 
5% of them have microcephaly.111  374 
 375 
ZIKV 376 
ZIKV infection in pregnancy and its possible link to a range of birth defects is currently the 377 
subject of intense investigation worldwide. There is now convincing evidence that ZIKV 378 
infection in pregnancy, especially in the first trimester, is associated with an increased risk of 379 
microcephaly. The risk of microcephaly associated with ZIKV infection was estimated as 95 per 380 
10,000 infected women in first trimester in French Polynesia.112 Congenital disease has 381 
predominantly been seen in Brazil, but this may spread across Latin America. Brasil et al 382 
followed up ZIKV affected pregnant women in Rio de Janeiro and found that 3.4% had 383 
microcephaly and 42% had abnormal clinical or radiological findings in the first month, mostly 384 
affecting the central nervous system.113 The spectrum of congenital Zika syndrome (CZS) 385 
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includes birth defects associated with microcephaly (including hearing loss and ophthalmological 386 
defects) and how they are related to timing of infection, and presence or absence of maternal 387 
symptoms, as well as the influence of other arboviral infections has yet to be fully delineated. 388 
Currently, most of what is known about CZS comes from neonates with microcephaly which 389 
appears to include syndrome-specific features such as partially collapsed skull, reduced cortical 390 
thickness and extensive subcortical calcifications.114,115 However, the full spectrum will only 391 
become clear when cohorts of infected mothers provide in-depth report of the clinical 392 
presentation. Brain damage or ocular lesions can be found in the absence of microcephaly and 393 
other features, as described in the appendix, are common.14,116,117  It is yet to be shown whether 394 
there is ongoing viral replication at the time of birth in congenital ZIKV infection. This will have 395 
important implications for the potential efficacy of postnatally administered antiviral therapy.  396 
 397 
Markers for Prognosis  398 
Microcephaly outcomes are varied, and more accurate prognosis at the time of diagnosis is one of 399 
the main aims of clinical evaluation of the neonate. Neuroimaging- for example crUS, CT and 400 
MRI-  has proven a useful predictive investigation and is warranted in neonates with severe 401 
microcephaly, or where a congenital infection is suspected.118 Whilst different modalities have 402 
specific advantages (e.g. good visibility of calcifications on CT, bedside availability of crUS), 403 
many structural abnormalities caused by disruptions in development can be identified across 404 
modalities. Typical abnormalities include intracranial calcifications, white matter abnormalities 405 
(e.g. periventricular leukomalacia, delayed myelination; best seen on MRI), gyration defects (e.g. 406 
polymicrogyria), and schizencephaly.12,119   407 
 408 
Long-term consequences and resulting disability in childhood  409 
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Long-term follow-up is recommended for infants with microcephaly and even for those with 410 
congenital infections and who are apparently unaffected at birth in order to manage evolving 411 
conditions and identify new manifestations early. In many cases, the cause of microcephaly will 412 
not be known and generic plans can be adopted to manage impairments and limit disability. The 413 
timing of the interventions vary in importance. Hearing screening for example needs to be done 414 
early to enable interventions to optimise language development. Other interventions, including 415 
psychosocial support and counselling,120 are required throughout childhood and into adult life.   416 
Where microcephaly occurs, recommendations are for early intervention to address associated 417 
impairments, calling upon a host of specialist medical and educational services.121 Currently, 418 
regular follow-up is recommended for ZIKV associated microcephaly for anthropometry, 419 
developmental and neurological assessments and also hearing and ophthalmological assessment 420 
where required over the first two years, with less frequent follow-up recommended for infants 421 
without microcephaly.1 Evidence-based therapy strategies exist that may improve cognitive 422 
outcomes and reduce disability.122 Interventions in early life, for example child stimulation,123 423 
maximise the plasticity of the developing brain, attenuating the consequences of the damage to 424 
the nervous system. But such recommendations ignore the realities of life in many countries. 425 
Issues begin at birth, for example, in some societies, children with visible disabilities are allowed 426 
to die in the neonatal period, either through active infanticide or through withdrawal of basic care 427 
such as feeding.124  428 
The provision of both recommended early diagnosis, and appropriate interventions may be 429 
severely limited in countries with only a handful of specialists, where early intervention 430 
programmes or inclusive education efforts remain rare and are largely urban-based. Based on a 431 
small but growing literature on disability, individuals with more severe disabilities are far less 432 
likely to receive appropriate medical care, attend school or are included in the social, economic or 433 
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religious life of their communities.125 This is compounded in poorer households, which often 434 
choose to invest limited resources on non-disabled children, whom they feel will be able to 435 
contribute to the household in future.126 Furthermore, recommendations for individuals with 436 
microcephaly tend to concentrate on early childhood, but anticipate little about their management, 437 
support or advocacy needs beyond pre-school years. While attitudes vary from society to society, 438 
overwhelmingly, persons with disabilities face increased risk of stigma, social isolation, abuse 439 
and poverty across their lifespan.127 440 
Infections that cause microcephaly are likely to disproportionately affect LMICs and within these 441 
countries, the poorest populations, who are more likely to live in crowded areas with inadequate 442 
housing and limited water and sanitation systems. Compounding this, poorer women are less 443 
likely to have access to family planning services, to access prenatal screening or, if needed, safe 444 
termination of pregnancy.128 445 
Although social protection schemes are beginning in many middle-income countries,129 the cost 446 
of raising and supporting a disabled child continues to be borne almost entirely by the immediate 447 
family. Households with disabled members are on average, poorer because of increased costs and 448 
because family members, in particular women, must take time away from income generating 449 
activities to provide care.130  450 
Improved services and support for affected individuals and families across the lifespan must be 451 
anticipated, and health professionals must work with civil society organisations, including 452 
disabled peoples organisations, to ensure these children and their families receive the medical, 453 
educational and social service support they need and are entitled to.131 454 
 455 
Conclusions 456 
We have summarised the epidemiology, clinical presentation and the current understanding of the 457 
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pathogenesis of the major congenital infections associated with microcephaly. Potential 458 
inconsistencies in the criteria used to diagnose microcephaly have been highlighted as well as 459 
limitations of current diagnostic methods in confirming an infectious aetiology. If microcephaly, 460 
as strictly defined by head circumference, is used as a screening tool, it will miss affected infants 461 
who do not manifest with a small head size. Many infants are likely to have subtle deficits 462 
needing more sensitive neurological and developmental assessments. Microcephaly is also 463 
usually only one manifestation in a syndrome and other assessments are required to identify the 464 
full spectrum of illness.  465 
ZIKV has brought the attention of the world to the problem of microcephaly. The extent of the 466 
disease burden resulting from ZIKV is still being clarified but it appears to be significant and is 467 
one of a number of infections associated with primary microcephaly. On an individual level, 468 
accurate diagnosis and thorough investigation of confirmed microcephaly can guide management 469 
and determine prognosis. On a population level, assessing the overall burden and contribution of 470 
different causes will guide future interventions and strategies for prevention. Preventing infection, 471 
where possible, must be prioritized. It is not within the scope of this review to fully consider 472 
health protection and primary prevention but key interventions exist, for example population 473 
immunisation for rubella and vector control for ZIKV. Pharmacological interventions are able to 474 
treat some congenital infections and therefore limit further damage to the child’s developing 475 
nervous system (CMV, HSV, T.gondii). Antiviral treatments are not currently available to treat 476 
ZIKV in pregnancy but vaccines are in development. Interventions to attenuate the effects of the 477 
developmental delay, and at the community or population level to minimize impairment caused 478 
by infections that can lead to microcephaly are all needed. More clinical and health system 479 
research is crucial to provide scalable interventions to reduce the disability associated with 480 
microcephaly. Many interventions designed to optimise neurodevelopmental outcomes in 481 
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infected infants will be common to all congenital infections and enhanced services for ZIKV 482 
follow up could potentially also be used in the future for the benefit of children severely affected 483 
by other congenital infections. 484 
Regions in which the infective burden is highest are also likely to be those where diagnosis and 485 
management is most lacking, creating a disproportionately large burden on populations that can 486 
least afford it. Inequities in access to optimised multidisciplinary care for children with 487 
neurodisability in areas with the highest rates of microcephaly means that the prognosis for those 488 
infants is often very poor. ZIKV has highlighted the issue of microcephaly and provides a timely 489 
opportunity to refocus on the whole group of infectious diseases which can affect the developing 490 
fetal brain and to redouble our efforts for prevention and treatment in the short- and long-term for 491 
those living with the frequently devastating consequences of such congenital infections. 492 
 493 
 494 
Panel: Clinical features suggestive of congenital infection in a neonate with 495 
microcephaly.132,133 496 
 Severe microcephaly (<-3 z-scores) 497 
 intrauterine growth restriction 498 
 hydrops fetalis 499 
 seizures  500 
 cataract and other visual abnormalities  501 
 hearing loss 502 
 congenital heart disease 503 
 hepatosplenomegaly 504 
 jaundice 505 
 characteristic rashes  506 
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Table 1. Summary of the microbiological, virological and maternal clinical features 
Organism Description Transmission Risk period for 
transmission of infection 
to the fetus 
Maternal signs and 
symptoms 
Prevention of infection and 
treatment of pregnant 
women  
CMV Betaherpes DNA 
virus 
Herpesviridae 
family 
Infectious body fluid (saliva, 
urine, breast milk, genital 
secretions, blood transfusion). 
Risk increases with 
gestational age, but earlier 
infection is associated with 
more severe congenital 
infection. 
Mostly asymptomatic or 
flu-like symptoms 
Treatment with antiviral 
medication not currently 
recommended outside of 
trial settings.  
Candidate vaccines are in 
development. Hyperimmune 
globulin has been trialled but 
has not as yet been shown to 
reduce transmission of CMV 
to the fetus.134  
HSV 1 & 2 Alphaherpes 
DNA viruses. 
Herpesviridae 
family 
Orogenital, genital-genital, 
transmitted during delivery 
through infected maternal 
genital tract. 
Virus shed with or without 
Risk is associated 
predominantly with 
primary infection late in 
pregnancy.  
Primary genital herpes 
infection may be 
asymptomatic but is often 
associated with 
mucocutaneous lesions.75 
Risk of perinatal 
transmission can be reduced 
by Caesarean section in the 
context of active genital 
lesions and suppressive 
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lesions present. Latent infection is 
subsequently established in 
dorsal root ganglia. 
Mucocutaneous lesions can 
then recur following viral 
reactivation.105 
aciclovir/valaciclovir given 
to the mother prior to 
delivery.135 
 
Rubella virus Single stranded 
RNA virus 
Togaviridae 
family 
Respiratory transmission. 
Humans are the only known 
host of rubella.136   
Risk of congenital disease 
in first 20 weeks; infection 
beyond this not associated 
with congenital defects. 
Primary maternal infection 
is associated with up to a 
50% risk of fetal 
infection.137 
Typically a mild self-
limiting illness 
Maculopapular rash, 
lymphadenopathy, malaise, 
arthralgia, fever.136   
Immunisation of girls to 
prevent individual cases and 
the whole population to 
interrupt transmission.  
Supportive management of 
the infection. 
T. gondii Obligate 
intracellular 
protozoan 
parasite 
 
Humans acquire infection 
mainly by consuming raw or 
undercooked meat containing 
cysts, by ingesting water or 
raw vegetables contaminated 
with oocysts, or by 
Risk of congenital 
transmission increases with 
gestational age at maternal 
infection: 15% (95% CI 
13–17) at 13 weeks and 
71% (95% CI 66-76) at 36 
Most acute T. gondii 
infections in 
immunocompetent 
pregnant women are 
subclinical; fever, 
lymphadenopathy and a 
Treatment with spiramycin 
and/or pyrimethamine-
sulphonamide of maternal 
toxoplasmosis diagnosed 
through prenatal screening is 
believed to reduce the risk of 
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transplacental transfer of 
tachyzoites during an acute 
infection. Tachyzoites invade 
host cells, multiply and 
disseminate, infecting 
multiple sites in the body 
including brain, eye, heart, 
skeletal muscle and 
placenta.138  
Toxoplasmosis reactivation in 
immunocompromised women 
may rarely be a cause. Blood 
transfusion or organ 
transplantation. 
The only definitive hosts are 
members of the cat family.138  
weeks.109 flu-like illness are the most 
common clinical signs and 
symptoms.138 
mother-to-child transmission 
and neurologic sequelae in 
the fetus in settings where 
low-virulence type II strains 
predominate, but this 
protective effect remains to 
be confirmed against more 
virulent atypical 
recombinant strains.101  
ZIKV 
(much 
knowledge 
still 
Single stranded 
RNA arbovirus 
Flaviridae 
The main vector is the Aedes 
mosquito. A. aegypti is 
considered of greatest global 
importance.139  
Risk of transmission 
appears to be throughout 
pregnancy 
Infection is often 
asymptomatic in adults 
with symptoms reported in 
approximately 20% of 
Primary prevention of 
mosquito bites. No treatment 
as yet.  
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provisional)  family 
 
There are 
currently two 
major lineages: 
one African 
(with two 
groups, the 
Uganda cluster 
and the Nigeria 
cluster) and one 
Asian/American.  
 
Also sexual transmission and 
potentially through infected 
blood transfusion.140   
Non-human hosts are thought 
mainly to include non-human 
primates, although evidence 
of infection has also been 
demonstrated in other 
mammals.139 
  
 
 
cases.141  
Common features include 
pruritic, maculopapular 
rash, low grade fever, 
arthritis/arthralgia, 
conjunctivitis, myalgia and 
headache.  
Has been associated with 
Guillain-Barré syndrome, 
myelitis and 
meningoencephalitis 
reported in adults.142  
Table 2: Diagnosis and treatment of infants 
Organism Diagnosis Treatment 
CMV CMV viral culture or PCR testing for DNA from urine or saliva 
obtained within the first three weeks of life. Retrospective diagnosis 
can be achieved from dried blood samples taken for newborn 
screening. Testing should be done as early as possible. 
Early treatment of confirmed symptomatic congenital CMV with IV 
ganciclovir or oral valganciclovir is currently recommended based 
on the results of 2 main trials.143-145 Results from randomised trials 
and observational studies have demonstrated improved hearing and 
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neurodevelopmental outcomes although questions remain regarding 
optimal treatment strategies, including when to treat and duration of 
therapy. 
HSV 1 & 2 PCR testing for viral DNA on surface swabs (conjunctivae, mucosal 
surfaces), cutaneous lesions, CSF, whole blood, and tracheal 
secretions where available. 
Intravenous high-dose acyclovir is indicated for confirmed neonatal 
HSV infections.146  
 
Rubella Isolation of rubella virus (or viral RNA) from the neonate, isolation 
of rubella IgM or persistent rubella IgG. The virus is most 
commonly isolated from nasopharyngeal samples, but can be from 
blood, urine, and CSF cultures.147 
Management is mainly supportive and involves monitoring for late 
emerging symptoms (e.g. hearing loss, endocrine problems). 
T. gondii Diagnosis is difficult if specific IgM and IgA antibodies are not 
detected in the serum or plasma at birth. CSF samples to detect IgM 
and IgA antibodies may confirm the diagnosis in infants with 
intracerebral lesions. 
Maternal IgG is detectable in the fetus for several months, generally 
disappearing completely within one year. Because specific IgG 
produced by congenitally infected newborns may be detected about 
12 weeks after birth, the presence of high IgG titres beyond this time 
is suggestive of congenital infection.95 
Congenital toxoplasmosis is treated with pyrimethamine and 
sulphonamide (sulphadiazine or sulphadoxine) with folinic acid to 
minimize pyrimethamine-associated hematologic toxicity. Up to 
85% of children with subclinical congenital infection, if left 
untreated, will later develop signs and symptoms of disease, such as 
chorioretinitis or developmental delays.148 
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ZIKV 
 
Testing for IgM antibody with capture ELISA using recombinant 
antigens in CSF or blood at birth indicate congenital infection; 
plaque reduction neutralisation tests are required to confirm 
monotypic antibody responses, although dengue and yellow fever do 
not cause congenital infections. Reverse-transcriptase PCR detects 
acute infections, positivity rare in neonates. Tests can be done on 
serum/plasma from cord blood or infant's peripheral blood. IgM 
detection in CSF of neonate is highly specific. 
Clinical management of complications, including dysphagia, 
irritability and epilepsy. Supportive care for neurocognitive delays, 
hearing and visual loss, and appropriate developmental follow-up. 
CNS = central nervous system, CSF = cerebrospinal fluid, PCR = polymerase chain reaction 
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Figure 1: Modelled population effects of insults to brain developmental  
* Bars represent the OFC distribution at birth (z-scores on x axis). The dark bar segments indicate 
the head circumference measurements of these “affected” children. The continuous line 
represents the reference population (no children “affected”), with a mean of 0 and SD of 1. 
Simulated populations were created using R language and environment for statistical 
computing.149 
If an otherwise normal population of 1000 infants (in which children's occipito-frontal 
circumferences (OFCs) are close to their expected values) is exposed to a congenital infection 
that limits brain development, a proportion of children are labelled as “normal” by being above 
the -2 z-scores (standard deviations (SD)) or -3 z-scores cut-offs but they may deviate from their 
“expected” OFC.  
Scenario 1 describes a congenital infection with a uniform shift to the left by 1 SD relative to the 
reference curve in 30% (randomly chosen) of affected children, roughly as expected in congenital 
toxoplasmosis acquired late in pregnancy. The remaining 70% children were not affected at all. 
In this hypothetical scenario, 6·5% of children fall below -2 z-score cut-off value for 
microcephaly; 0·9% below the -3 z-scores. Only 65 of the 300 (21·7%) of the “affected” children 
will actually be classified as “microcephalic” by using the -2 z-score cut-off. Only children whose 
“ideal” OFC would be less than -1 SD of the expected mean (expected proportion of 15·9% in a 
Scenario 1 Scenario 1
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healthy population), would actually be diagnosed as “microcephalic” after the 1 SD shift caused 
by the infection.  
Scenario 2 is a congenital infection where OFC is shifted to the left by 2 SD in 10% of children, 
roughly as expected for congenital toxoplasmosis acquired early in pregnancy. In this 
hypothetical scenario, 6·5% of children fall below -2 z-score cut-off value for microcephaly; 
1·4% below the -3 z-scores. Here, 65% of “affected” children will fall below the cut-off value of 
-2 SD.  
By counting the number of children below a given cut-off value we are severely underestimating 
not only the proportion of children who have been relatively mildly affected (Scenario 1) but also 
that of children who have been more severely affected (Scenario 2). Moreover, although 
Scenarios 1 and 2 represent conditions varying in severity which affect different proportions of 
children in the population, in both examples the prevalence of microcephaly, estimated by 
applying the -2 z-score cut-off, would be quite similar (around 6.5%).  
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Figure 2. Factors that may influence neuronal and neural progenitor populations and lead 
to microcephaly or macrocephaly 
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Figure 3: Measurement of occipito-frontal circumference (OFC) in the neonate  
Measurements of OFC can be variable and user dependent. To aid robust measurements, a non-
stretchable tape should be used and placed above the ears, covering the broadest part of the 
forehead, and the most prominent area of the occiput as shown. The largest measured 
circumference of three repeat measures should be used and recorded to the nearest millimeter. In 
neonates, the most robust measurements are achieved at >24h of age when post-partum skull 
modelling has subsided. 
 
 
Search strategy 
Pubmed, Embase and Google Scholar were searched, with no language or date restrictions 
(search end date: 31 March 2017), for the following terms and reference lists were searched for 
additional citations: 
 (Cytomegalovirus or CMV or Rubella or MMR or Zika or HSV or herpes or toxoplasma or 
toxoplasmosis) and (seroprevalence or prevalence or incidence) 
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 (congenital pathogenic infections or pathogenic infections) and (brain disorders or microcephaly) 
 (pathogens or virus or pathogen or viral) and microcephaly  
 (Cytomegalovirus or CMV or Rubella or MMR or Zika or HSV or herpes or toxoplasma or 
toxoplasmosis) and (brain or brain disorder or brain development or brain defects) 
 (cytomegalovirus or rubella or toxoplasmosis or herpes simplex or varicella or chikungunya or 
West Nile virus or HIV or syphilis) AND microcephaly NOT Zika 
 
Conflicts of interest 
We declare that we have no conflicts of interest. 
 
Acknowledgements 
Fabien Lafaille who advised on HSV and brain development. Joint MRC/Wellcome Trust 
(099175/Z/12/Z) Human Developmental Biology Resource (www.hdbr.org) for providing 
a human brain section shown in Figure 2.  
 
Author contributions 
DD and IA conceived the work. AB, DD, JoB, MUF, PA and RR undertook the literature 
reviews. AB, AJC, DD, JoB, JuB, LCR, MAC, MUF, NEG, PA and RR wrote the sections of the 
draft. All authors interpreted and critically revised the draft.  
 
Funding 
There was no specific funding for this work. DD receive salary support from NIHR, and PA from 
Royal Society, Dorothy Hodgkin Fellowship. IA is supported by NIHR (SRF-2011-04-001; NF-
SI-0616-10037). JuB receives funding from the NIHR UCL/UCLH Biomedical Research Centre. 
 33 
LCR is partially funded by the European Union’s Horizon 2020 research and innovation program 
under Zika- PLAN grant agreement No. 734584.  
 
Ethics approval 
Not applicable. This a review of published literature.  
 
References 
1. World Health Organization. Screening, assessment and management of neonates and infants with 
complications associated with Zika virus exposure in utero. Rapid Advice Guideline, 2016. 
2. Ashwal S, Michelson D, Plawner L, Dobyns WB, Quality Standards Subcommittee of the 
American Academy of N, the Practice Committee of the Child Neurology S. Practice parameter: 
Evaluation of the child with microcephaly (an evidence-based review): report of the Quality Standards 
Subcommittee of the American Academy of Neurology and the Practice Committee of the Child 
Neurology Society. Neurology 2009; 73(11): 887-97. 
3. Leviton A, Holmes LB, Allred EN, Vargas J. Methodologic issues in epidemiologic studies of 
congenital microcephaly. Early Hum Dev 2002; 69(1-2): 91-105. 
4. Victora CG, Schuler-Faccini L, Matijasevich A, Ribeiro E, Pessoa A, Barros FC. Microcephaly in 
Brazil: how to interpret reported numbers? Lancet 2016; 387(10019): 621-4. 
5. World Health Organization. WHO Child Growth Standards. 
http://www.who.int/childgrowth/en/. 
6. Villar J, Cheikh Ismail L, Victora CG, et al. International standards for newborn weight, length, 
and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the 
INTERGROWTH-21st Project. Lancet 2014; 384(9946): 857-68. 
7. Morris JK, Rankin J, Garne E, et al. Prevalence of microcephaly in Europe: population based 
study. BMJ 2016; 354: i4721. 
8. Woods CG. Human microcephaly. Curr Opin Neurobiol 2004; 14(1): 112-7. 
9. Passemard S, Kaindl AM, Verloes A. Microcephaly. Handb Clin Neurol 2013; 111: 129-41. 
10. Barkovich AJ, Kuzniecky RI, Jackson GD, Guerrini R, Dobyns WB. A developmental and genetic 
classification for malformations of cortical development. Neurology 2005; 65(12): 1873-87. 
11. Szabo N, Pap C, Kobor J, Svekus A, Turi S, Sztriha L. Primary microcephaly in Hungary: 
epidemiology and clinical features. Acta paediatrica 2010; 99(5): 690-3. 
12. von der Hagen M, Pivarcsi M, Liebe J, et al. Diagnostic approach to microcephaly in childhood: a 
two-center study and review of the literature. Dev Med Child Neurol 2014; 56(8): 732-41. 
13. Graham KA, Fox DJ, Talati A, et al. Prevalence and Clinical Attributes of Congenital 
Microcephaly - New York, 2013-2015. MMWR Morb Mortal Wkly Rep 2017; 66(5): 125-9. 
14. Franca GV, Schuler-Faccini L, Oliveira WK, et al. Congenital Zika virus syndrome in Brazil: a 
case series of the first 1501 livebirths with complete investigation. Lancet 2016. 
15. Oliveira Melo AS, Malinger G, Ximenes R, Szejnfeld PO, Alves Sampaio S, Bispo de Filippis 
AM. Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg? 
Ultrasound Obstet Gynecol 2016; 47(1): 6-7. 
16. Dolk H. The predictive value of microcephaly during the first year of life for mental retardation at 
seven years. Dev Med Child Neurol 1991; 33(11): 974-83. 
 34 
17. Heinonen K, Raikkonen K, Pesonen AK, et al. Prenatal and postnatal growth and cognitive 
abilities at 56 months of age: a longitudinal study of infants born at term. Pediatrics 2008; 121(5): e1325-
33. 
18. Woods CG, Parker A. Investigating microcephaly. Arch Dis Child 2013; 98(9): 707-13. 
19. Krauss MJ, Morrissey AE, Winn HN, Amon E, Leet TL. Microcephaly: an epidemiologic analysis. 
Am J Obstet Gynecol 2003; 188(6): 1484-9; discussion 9-90. 
20. O'Rahilly R, Muller F. Developmental Stages in Human Embryos. Washington: Carnegie 
Institution of Washington Publication 637; 1987. 
21. Chenn A, Walsh CA. Regulation of Cerebral Cortical Size by Control of Cell Cycle Exit in Neural 
Precursors. Science 2002; 297(5580): 365-9. 
22. Sahara S OLD. Fgf10 regulates transition period of cortical stem cell differentiation to radial glia 
controlling generation of neurons and basal progenitors. Neuron 2009; 63: 48-62. 
23. Buchman JJ TH, Zhou Y, Frank CL, Xie Z, Tsai LH. Cdk5rap2 interacts with pericentrin to 
maintain the neural progenitor pool in the developing neocortex. Neuron 2010; 66: 386-402. 
24. Marthiens V RM, Pennetier C, Tessier S, Paul-Gilloteaux P, Basto R. Centrosome amplification 
causes microcephaly. Nat Cell Biol 2013; 15: 731-40. 
25. Chen JF ZY, Wilde J, Hansen KC, Lai F, Niswander L. Microcephaly disease gene Wdr62 
regulates mitotic progression of embryonic neural stem cells and brain size. Nat Commun 2014; 5: 3885. 
26. Lancaster MA RM, Martin CA, Wenzel D, Bicknell LS, Hurles ME, Homfray T, Penninger JM, 
Jackson AP, Knoblich JA. Cerebral organoids model human brain development and microcephaly. . 
Nature 2013; 501: 373-9. 
27. Cooper LZ, Ziring PR, Ockerse AB, Fedun BA, Kiely B, Krugman S. Rubella-Clinical 
manifestations and management. Am J Dis Child 1969; 118: 18-29. 
28. Webster WS. Teratogen update: congenital rubella. Teratology 1998; 58: 13-23. 
29. Driggers RW, Ho CY, Korhonen EM, et al. Zika Virus Infection with Prolonged Maternal 
Viremia and Fetal Brain Abnormalities. N Engl J Med 2016; 374(22): 2142-51. 
30. Mlakar J, Korva M, Tul N, et al. Zika Virus Associated with Microcephaly. N Engl J Med 2016; 
374(10): 951-8. 
31. Feldman B, Yinon Y, Tepperberg Oikawa M, Yoeli R, Schiff E, Lipitz S. Pregestational, 
periconceptional, and gestational primary maternal cytomegalovirus infection: prenatal diagnosis in 508 
pregnancies. American journal of obstetrics and gynecology 2011; 4: e1-6. 
32. Lipitz S, Yinon Y, Malinger G, et al. Risk of cytomegalovirus-associated sequelae in relation to 
time of infection and findings on prenatal imaging. Ultrasound Obstet Gynecol 2013; 41: 508-14. 
33. McAuley JB. Congenital Toxoplasmosis J Pediatric Infect Dis Soc 2014; Suppl 1: S30–S5. 
34. Marquez L, Levy ML, Munoz FM, Palazzi DL. A Report of Three Cases and Review of 
Intrauterine Herpes Simplex Virus Infection. Pediatr Infect Dis J 2011; 30(2): 153-7. 
35. Hutto C, Arvin A, Jacobs R, et al. Intrauterine herpes simplex virus infections. J Pediatr 1987; 
110(1): 97-101. 
36. Barefoot KH, Little GA, Ornvold KT. Fetal Demise Due to Herpes Simplex Virus: An Illustrated 
Case Report. Journal of Perinatology  
 2002; 22: 86-8. 
37. Odeberg J, Wolmer N, Falci S, Westgren M, Seiger A, Söderberg-Nauclér C. Human 
cytomegalovirus inhibits neuronal differentiation and induces apoptosis in human neural precursor cells. J 
Virol 2006; 80: 8929-39. 
38. Johansson AB, Rassart A, Blum D, Van Beers D, Liesnard C. Lower-limb hypoplasia due to 
intrauterine infection with herpes simplex virus type 2: possible confusion with intrauterine varicella-
zoster syndrome. Clin Infect Dis 2004; 38(7): 57-62. 
39. Lazar M, Perelygina L, Martines R, et al. Immunolocalization and Distribution of Rubella Antigen 
in Fatal Congenital Rubella Syndrome. EBioMedicine 2015; 3: 86-92. 
40. Dang J, Tiwari SK, Lichinchi G, et al. Zika Virus Depletes Neural Progenitors in Human Cerebral 
Organoids through Activation of the Innate Immune Receptor TLR3. Cell Stem Cell 2016; 19(2): 258-65. 
 35 
41. Qian X, Nguyen HN, Song MM, et al. Brain-Region-Specific Organoids Using Mini-bioreactors 
for Modeling ZIKV Exposure. Cell 2016; 165(5): 1238-54. 
42. Lafaille FG, Pessach IM, Zhang SY, et al. Impaired intrinsic immunity to HSV-1 in human iPSC-
derived TLR3-deficient CNS cells. Nature 2012; 491: 769-73. 
43. Garcez PP, Loiola EC, Madeiro da Costa R, et al. Zika virus impairs growth in human 
neurospheres and brain organoids. Science 2016; 352(6287): 816-8. 
44. Luo MH, Hannemann H, Kulkarni AS, Schwartz PH, O'Dowd JM, Fortunato EA. Human 
cytomegalovirus infection causes premature and abnormal differentiation of human neural progenitor cells. 
J Virol 2010; 84: 3528-41. 
45. Li XJ, Liu XJ, Yang B, et al. Human Cytomegalovirus Infection Dysregulates the Localization 
and Stability of NICD1 and Jag1 in Neural Progenitor Cells. J Virol 2015; 89: 6792-804. 
46. D'Aiuto L, Di Maio R, Heath B, et al. Human induced pluripotent stem cell-derived models to 
investigate human cytomegalovirus infection in neural cells. PLoS One 2012; 7: e49700. . 
47. Rolland M, Li X, Sellier Y, et al. PPARgamma Is Activated during Congenital Cytomegalovirus 
Infection and Inhibits Neuronogenesis from Human Neural Stem Cells. PLoS Pathog 2016; 12(4): 
e1005547. 
48. Braun E, Zimmerman T, Hur TB, et al. Neurotropism of herpes simplex virus type 1 in brain 
organ cultures. J Gen Virol 2006; 87: 2827-37. 
49. Hu S, Rotschafer JH, Lokensgard JR, Cheeran MC-J. Activated CD8+ T Lymphocytes Inhibit 
Neural Stem/Progenitor Cell Proliferation: Role of Interferon-Gamma. PLoS ONE 2014; 9(8): e105219. 
50. Nguyen TV, Pham VH, Abe K. Pathogenesis of Congenital Rubella Virus Infection in Human 
Fetuses: Viral Infection in the Ciliary Body Could Play an Important Role in Cataractogenesis. 
EBioMedicine 2014; 2: 59-63. 
51. Rorke LB, Fabiyi A, Elizan TS, Sever JL. Experimental cerebrovascular lesions in congenital and 
neonatal rubella-virus infections of ferrets. Lancet 1968; 2: 153-4. 
52. Tondury G, Smith DW. Fetal rubella pathology. J Pediat 1966; 68: 867. 
53. Cugola FR, Fernandes IR, Russo FB, et al. The Brazilian Zika virus strain causes birth defects in 
experimental models. Nature 2016; 534: 267-71. 
54. Tang H, Hammack C, Ogden SC, et al. Zika Virus Infects Human Cortical Neural Progenitors and 
Attenuates Their Growth. Cell Stem Cell 2016; (18): 587-90. 
55. Hamel R, Liegeois F, Wichit S, et al. Zika virus: epidemiology, clinical features and host-virus 
interactions. Microbes Infect 2016; 18(7-8): 441-9. 
56. Nowakowski TJ, Pollen AA, Di Lullo E, andoval-Espinosa C, Bershteyn M, Kriegstein AR. 
Expression Analysis Highlights AXL as a Candidate Zika Virus Entry Receptor in Neural Stem Cells. Cell 
Stem Cell 2016; 5: 591-6. 
57. Onorati M, Li Z, Liu F, et al. Zika Virus Disrupts Phospho-TBK1 Localization and Mitosis in 
Human Neuroepithelial Stem Cells and Radial Glia. Cell Rep 2016; 16(10): 2576-92. 
58. Wells MF, Salick MR, Wiskow O, et al. Genetic Ablation of AXL Does Not Protect Human 
Neural Progenitor Cells and Cerebral Organoids from Zika Virus Infection. Cell Stem Cell 2016; 19(6): 
703-8. 
59. Pillai S, Nguyen J, Johnson J, Haura E, Coppola D, Chellappan S. Tank binding kinase 1 is a 
centrosome-associated kinase necessary for microtubule dynamics and mitosis. Nat Commun 2015; 6: 
10072. 
60. Li C, Xu D, Ye Q, et al. Zika Virus Disrupts Neural Progenitor Development and Leads to 
Microcephaly in Mice. Cell Stem Cell 2016; 19: 120-6. 
61. Wu KY, Zuo GL, Li XF, et al. Vertical transmission of Zika virus targeting the radial glial cells 
affects cortex development of offspring mice. Cell Res 2016; 26: 645-54. 
62. Adams Waldorf KM, Stencel-Baerenwald JE, Kapur RP, et al. Fetal brain lesions after 
subcutaneous inoculation of Zika virus in a pregnant nonhuman 
primate. Nat Med 2016; 22(11): 1256-9. 
63. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The “silent” global burden of 
congenital cytomegalovirus. Clinical microbiology reviews 2013; 26(1): 86-102. 
 36 
64. Sheevani, Jindal N, Aggarwal A. A pilot seroepidemiological study of cytomegalovirus infection 
in women of child bearing age. Indian journal of medical microbiology 2005; 23(1): 34. 
65. Schoenfisch AL, Dollard SC, Amin M, et al. Cytomegalovirus (CMV) shedding is highly 
correlated with markers of immunosuppression in CMV-seropositive women. Journal of medical 
microbiology 2011; 60(6): 768-74. 
66. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic 
characteristics associated with infection. Reviews in medical virology 2010; 20(4): 202-13. 
67. Alanen A, Kahala K, Vahlberg T, Koskela P, Vainionpää R. Seroprevalence, incidence of prenatal 
infections and reliability of maternal history of varicella zoster virus, cytomegalovirus, herpes simplex 
virus and parvovirus B19 infection in South-Western Finland. BJOG: An International Journal of 
Obstetrics & Gynaecology 2005; 112(1): 50-6. 
68. Seo S, Cho Y, Park J. Serologic screening of pregnant Korean women for primary human 
cytomegalovirus infection using IgG avidity test. Korean J Lab Med 2009; 29(6): 557-62. 
69. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital 
cytomegalovirus (CMV) infection. Reviews in medical virology 2007; 17(4): 253-76. 
70. Ornoy A, Diav-Citrin O. Fetal effects of primary and secondary cytomegalovirus infection in 
pregnancy. Reproductive toxicology 2006; 21(4): 399-409. 
71. Picone O, Vauloup-Fellous C, Cordier AG, et al. A series of 238 cytomegalovirus primary 
infections during pregnancy: description and outcome. Prenatal diagnosis 2013; 33(8): 751-8. 
72. Britt W. Controversies in the natural history of congenital human cytomegalovirus infection: the 
paradox of infection and disease in offspring of women with immunity prior to pregnancy. Med Microbiol 
Immunol 2015; 204(3): 263-71. 
73. Society for Maternal-Fetal M, Hughes BL, Gyamfi-Bannerman C. Diagnosis and antenatal 
management of congenital cytomegalovirus infection. American journal of obstetrics and gynecology 
2016; 214(6): B5-B11. 
74. Khamduang W, Jourdain G, Sirirungsi W, et al. The interrelated transmission of HIV-1 and 
cytomegalovirus during gestation and delivery in the offspring of HIV-infected mothers. Journal of 
acquired immune deficiency syndromes 2011; 58(2): 188-92. 
75. Pinninti SG, Kimberlin DW. Neonatal herpes simplex virus infections. Pediatr Clin North Am 
2013; 60(2): 351-65. 
76. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes 
simplex virus type 2 infection. Bulletin of the World Health Organization 2008; 86(10): 805-12A. 
77. Looker KJ, Magaret AS, Turner KM, Vickerman P, Gottlieb SL, Newman LM. Global estimates 
of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS One 2015; 10(1): e114989. 
78. Vynnycky E, Adams EJ, Cutts FT, et al. Using Seroprevalence and Immunisation Coverage Data 
to Estimate the Global Burden of Congenital Rubella Syndrome, 1996-2010: A Systematic Review. PloS 
one 2016; 11(3): e0149160. 
79. World Health Organization. WHO | Rubella fact sheet. WHO 2016. 
80. Pandolfi E, Gesualdo F, Rizzo C, et al. Global seroprevalence of rubella among pregnant and 
childbearing age women: a meta-analysis. Eur J Public Health 2017. 
81. Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J 
Parasitol 2000; 30(12-13): 1217-58. 
82. Jones JL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB. Toxoplasma gondii 
infection in the United States: seroprevalence and risk factors. American journal of epidemiology 2001; 
154(4): 357-65. 
83. Torgerson PR, Mastroiacovo P. The global burden of congenital toxoplasmosis: a systematic 
review. Bulletin of the World Health Organization 2013; 91(7): 501-8. 
84. Wang Z-D, Wang S-C, Liu H-H, et al. Prevalence and burden of Toxoplasma gondii infection in 
HIV-infected people: a systematic review and meta-analysis. The Lancet HIV; 4(4): e177-e88. 
85. Duffy MR, Chen T-H, Hancock WT, et al. Zika Virus Outbreak on Yap Island, Federated States 
of Micronesia. New England Journal of Medicine 2009; 360(24): 2536-43. 
 37 
86. Aubry M, Teissier A, Huart M, et al. Zika virus seroprevalence, French Polynesia, 2014–2015. 
Emerging infectious diseases 2017. 
87. World Health Organization. WHO | Zika situation report. WHO 2017. 
88. Coelho FC, Durovni B, Saraceni V, et al. Sexual transmission causes a marked increase in the 
incidence of Zika in women in Rio de Janeiro, Brazil. bioRxiv 2016: 055459. 
89. Health Protection Agency Rash Guidance Working Group. Guidance on Viral Rash in Pregnancy. 
Investigation, Diagnosis and Management of Viral Rash Illness, or Exposure to Viral Rash Illness, in 
Pregnancy. London: Public Health England, 2011. 
90. Pass RF, Boppana S, Jeffries DJ, Hudson CN. Viral infection in obstetrics and gynaecology. New 
York: Arnold; 1999. 
91. Best JM. Rubella. Semin Fetal Neonatal Med 2007; 12(3): 182-92. 
92. Mendelson E, Aboudy Y, Smetana Z, Tepperberg M, Grossman Z. Laboratory assessment and 
diagnosis of congenital viral infections: Rubella, cytomegalovirus (CMV), varicella-zoster virus (VZV), 
herpes simplex virus (HSV), parvovirus B19 and human immunodeficiency virus (HIV). Reproductive 
toxicology 2006; 21(4): 350-82. 
93. Lazzarotto T, Guerra B, Lanari M, Gabrielli L, Landini MP. New advances in the diagnosis of 
congenital cytomegalovirus infection. J Clin Virol 2008; 41(3): 192-7. 
94. DPDx Laboratory Identification of Parasitic Diseases of Public Health Concern. Toxoplasmosis. 
2015. http://www.cdc.gov/dpdx/toxoplasmosis/dx.html (accessed 26/10/16). 
95. Petersen E. Toxoplasmosis. Semin Fetal Neonatal Med 2007; 12(3): 214-23. 
96. Dard C, Fricker-Hidalgo H, Brenier-Pinchart MP, Pelloux H. Relevance of and New 
Developments in Serology for Toxoplasmosis. Trends in parasitology 2016; 32(6): 492-506. 
97. Rorman E, Zamir CS, Rilkis I, Ben-David H. Congenital toxoplasmosis--prenatal aspects of 
Toxoplasma gondii infection. Reproductive toxicology 2006; 21(4): 458-72. 
98. Alanen A, Hukkanen V. Herpes simplex virus DNA in amniotic fluid without neonatal infection. 
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000; 
30(2): 363-7. 
99. Calvet G, Aguiar RS, Melo AS, et al. Detection and sequencing of Zika virus from amniotic fluid 
of fetuses with microcephaly in Brazil: a case study. Lancet Infect Dis 2016; 16(6): 653-60. 
100. World Health Organization. Immunization coverage, 2016. 
101. McLeod R, Kieffer F, Sautter M, Hosten T, Pelloux H. Why prevent, diagnose and treat 
congenital toxoplasmosis? Mem Inst Oswaldo Cruz 2009; 104(2): 320-44. 
102. Cheeran MC, Lokensgard JR, Schleiss MR. Neuropathogenesis of congenital cytomegalovirus 
infection: disease mechanisms and prospects for intervention. Clinical microbiology reviews 2009; 22(1): 
99-126, Table of Contents. 
103. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory 
sequelae and mortality associated with congenital cytomegalovirus infection. Reviews in medical virology 
2007; 17(5): 355-63. 
104. Dreher AM, Arora N, Fowler KB, et al. Spectrum of disease and outcome in children with 
symptomatic congenital cytomegalovirus infection. The Journal of pediatrics 2014; 164(4): 855-9. 
105. Kimberlin DW. Neonatal Herpes Simplex Infection. Clinical microbiology reviews 2004; 17(1): 
1-13. 
106. Miller E, Cradock-Watson JE, Pollock TM. Consequences of confirmed maternal rubella at 
successive stages of pregnancy. The Lancet 1982; 8302: 781-4. 
107. Givens KT, Lee DA, Jones T, Ilstrup DM. Congenital rubella syndrome: ophthalmic 
manifestations and associated systemic disorders. Br J Ophthalmol 1993; 77(6): 358-63. 
108. Reef SE, Plotkin S, Cordero JF, et al. Preparing for Elimination of Congenital Rubella Syndrome 
(CRS): Summary of a Workshop on CRS Elimination in the United States. Clinical infectious diseases : 
an official publication of the Infectious Diseases Society of America 2000; 31(1): 85-95. 
109. Syrocot study group, Thiebaut R, Leproust S, Chene G, Gilbert R. Effectiveness of prenatal 
treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet 2007; 
369(9556): 115-22. 
 38 
110. Cortina-Borja M, Tan HK, Wallon M, et al. Prenatal treatment for serious neurological sequelae 
of congenital toxoplasmosis: an observational prospective cohort study. PLoS Med 2010; 7(10). 
111. Capobiango JD, Bregano RM, Navarro IT, et al. Congenital toxoplasmosis in a reference center of 
Parana, Southern Brazil. Braz J Infect Dis 2014; 18(4): 364-71. 
112. Cauchemez S, Besnard M, Bompard P, et al. Association between Zika virus and microcephaly in 
French Polynesia, 2013–15: a retrospective study. The Lancet 2016; 387(10033): 2125-32. 
113. Brasil P, Pereira JP, Jr., Raja Gabaglia C, et al. Zika Virus Infection in Pregnant Women in Rio de 
Janeiro - Preliminary Report. N Engl J Med 2016. 
114. Moore CA, Staples JE, Dobyns WB, et al. Characterizing the Pattern of Anomalies in Congenital 
Zika Syndrome for Pediatric Clinicians. JAMA Pediatr 2017; 171(3): 288-95. 
115. Melo AS, Aguiar RS, Amorim MM, et al. Congenital Zika Virus Infection: Beyond Neonatal 
Microcephaly. JAMA Neurol 2016; 73(12): 1407-16. 
116. Ventura CV, Maia M, Dias N, Ventura LO, Belfort R, Jr. Zika: neurological and ocular findings 
in infant without microcephaly. Lancet 2016; 387(10037): 2502. 
117. Reynolds MR, Jones AM, Petersen EE, et al. Vital Signs: Update on Zika Virus-Associated Birth 
Defects and Evaluation of All U.S. Infants with Congenital Zika Virus Exposure - U.S. Zika Pregnancy 
Registry, 2016. MMWR Morb Mortal Wkly Rep 2017; 66(13): 366-73. 
118. Noyola DE, Demmler GJ, Nelson CT, et al. Early predictors of neurodevelopmental outcome in 
symptomatic congenital cytomegalovirus infection. The Journal of pediatrics 2001; 138(3): 325-31. 
119. Abdel Razek AA, Kandell AY, Elsorogy LG, Elmongy A, Basett AA. Disorders of cortical 
formation: MR imaging features. AJNR Am J Neuroradiol 2009; 30(1): 4-11. 
120. World Health Organization. Psychosocial support for pregnant women and for families with 
microcephaly and other neurological complications in the context of Zika virus. Interim guidance for 
health-care providers, 2016. 
121. Centers for Disease Control. Facts about Microcephaly. 2016. 
http://www.cdc.gov/ncbddd/birthdefects/microcephaly.html (accessed 15 July 2016). 
122. Holt RL, Mikati MA. Care for child development: basic science rationale and effects of 
interventions. Pediatr Neurol 2011; 44(4): 239-53. 
123. Britto PR, Lye SJ, Proulx K, et al. Nurturing care: promoting early childhood development. 
Lancet 2016. 
124. UNICEF. Violence against Children with Disabilities. Report for UNICEF/United Nations 
Secretary General’s Office. New York: UNICEF, 2005. 
125. World Health Organization, World Bank. World Report on Disability, 2011. 
126. UNICEF. Children with Disabilities, 2012. 
127. Groce N. Disability, Public Health and Social Injustice. In: Levy B, Sidel, V. , ed. Social Injustice 
and Public Health. 2nd ed. Oxford: Oxford University Press; 2014. 
128. Yamin A. Health, Human Rights and the Zika Virus. Health and Human Rights 2016. 
129. Palmer M. Disability and Poverty: A Conceptual Review. Journal of Disability Policy Studies 
2011; 21(4): 210-8. 
130. Mitra S, Posarac A, Vick B. Disability and Poverty in Developing Countries: A Multidimensional 
Study. World Development 2013; 41: 1-18. 
131. United Nations. UN Convention on the Rights of Persons with Disabilities. 2006. 
132. Klein JO, Remington JS. Current concepts of infections of the fetus and newborn infant  In: 
Remington JS, Klein JO, eds. Infectious Disease of the Fetus and Newborn Infant. 4th ed. Philadelphia: 
WB Saunders Co; 1995: 1–16. 
133. Johnson KE. Overview of TORCH infections. In: Weisman LE, Edwards MS, eds. UptoDate; 
2015. 
134. Leruez-Ville M, Ville Y. Optimum treatment of congenital cytomegalovirus infection. Expert Rev 
Anti Infect Ther 2016; 14(5): 479-88. 
135. Kimberlin DW, Baley J, Committee on infectious d, Committee on f, newborn. Guidance on 
management of asymptomatic neonates born to women with active genital herpes lesions. Pediatrics 
2013; 131(2): e635-46. 
 39 
136. Lee J, Bowden DS. Rubella Virus Replication and Links to Teratogenicity Clinical microbiology 
reviews 2000; 13(4): 571–87. 
137. Silasi M, Cardenas I, Kwon J-Y, Racicot K, Aldo P, Mor G. Viral infections during pregnancy. 
American Journal of Reproductive Immunology 2015; 73(3): 199-213. 
138. Montoya JG, Liesenfeld O. Toxoplasmosis. The Lancet 2004; 363(9425): 1965-76. 
139. Wikan N, Smith DR. Zika virus: history of a newly emerging arbovirus. Lancet Infect Dis 2016; 
16(7): e119-e26. 
140. Waddell LA, Greig JD. Scoping Review of the Zika Virus Literature. PLoS One 2016; 11(5): 
e0156376. 
141. Bharucha T, Breuer J. Review: A neglected Flavivirus: an update on Zika virus in 2016 and the 
future direction of research. Neuropathol Appl Neurobiol 2016; 42(4): 317-25. 
142. Petersen LR, Jamieson DJ, Powers AM, Honein MA. Zika Virus. N Engl J Med 2016; 374(16): 
1552-63. 
143. Kimberlin DW, Jester PM, Sanchez PJ, et al. Valganciclovir for symptomatic congenital 
cytomegalovirus disease. N Engl J Med 2015; 372(10): 933-43. 
144. Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in 
symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, 
controlled trial. The Journal of pediatrics 2003; 143(1): 16-25. 
145. Shah T, Luck S, Sharland M, Kadambari S, Heath P, Lyall H. Fifteen-minute consultation: 
diagnosis and management of congenital CMV. Archives of disease in childhood Education and practice 
edition 2016. 
146. Kimberlin DW, Lin CY, Jacobs RF, et al. Safety and efficacy of high-dose intravenous acyclovir 
in the management of neonatal herpes simplex virus infections. Pediatrics 2001; 108(2): 230-8. 
147. Plotkin SA, Reef SE, Cooper LZ, Alford CA. Rubella. In: Remington JS, Klein JO, Wilson CB, 
Baker CJ, eds. Infectious Diseases of the Fetus and Newborn Infant. 7th ed. Philadelphia: Elsevier 
Saunders; 2011: 861. 
148. Daffos F, Forestier F, Capella-Pavlovsky M, et al. Prenatal management of 746 pregnancies at 
risk for congenital toxoplasmosis. N Engl J Med 1988; 318(5): 271-5. 
149. R Development Core Team. R: A Language and Environment for Statistical  Computing, R 
Foundation for Statistical Computing. Vienna, Austria 2011. 
 
